IL17RB and ovarian carcinoma: Supporting our observation of ovarian lineage specificity, CRL4 has been identified as a potential therapeutic target in ovarian cancers,38, 67 and these screening efforts underscore the promise of developing pharmacological inhibitors of E3 ligase complexes for cancer treatment.